Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease

Digestive and Liver Disease

Volumn 46, Issue 11, 2014, Pages 963-968

  Annese, Vito ^a   Vecchi, Maurizio ^b   Bossa, Fabrizio ^c   Calabrese, Emma ^d   Daperno, Marco ^e   Rizzello, Fernando ^f   Rispo, Antonio ^g   Saibeni, Simone ^h   Armuzzi, Alessandro ⁱ   Biancone, Livia ^d   Castiglione, Fabiana ^g   Comberlato, Michele ^j   Cucchiara, Salvatore ^k   Danese, Silvio ^l   D'Incà, Renata ^m   Fiorino, Gionata ^l   Fries, Walter ⁿ   Gionchetti, Paolo ^f   Kohn, Anna ^o   Latella, Giovanni ^p   Meucci, Gimmy ^q   Orlando, Ambrogio ^r   Papi, Claudio ^s   Principi, Beatrice ^t   more..

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Division of Gastroenterology IRCCS CSS Hospital San Giovanni   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e MAURIZIANO HOSPITAL   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^h FATEBENEFRATELLI HOSPITAL   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j Division of Gastroenterology Regional Hospi tal   (Italy)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^m UNIVERSITY OF PADOVA   (Italy)

ⁿ UNIVERSITY OF MESSINA   (Italy)

^o ACO San Filippo Neri   (Italy)

^p UNIVERSITY OF L'AQUILA   (Italy)

^q San Giuseppe Hospital   (Italy)

^r Unit of Medicin 2 AO Villa Sofia CervelloHospitals   (Italy)

^s SAN FILIPPO NERI HOSPITAL   (Italy)

^t UNIVERSITY OF BARI   (Italy)

more..

Author keywords

Anti TNF ; Biosimilars; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; BIOSIMILAR AGENT; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; NATALIZUMAB; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BIOLOGICAL THERAPY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; HUMAN; INFLAMMATORY BOWEL DISEASE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PHYSICIAN; PRACTICE GUIDELINE; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; ADULT; DRUG APPROVAL; FEMALE; FOLLOW UP; FORECASTING; INFLAMMATORY BOWEL DISEASES; ITALY; MALE; MEDICAL SOCIETY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; FEMALE; FOLLOW-UP STUDIES; FORECASTING; GASTROINTESTINAL AGENTS; GUIDELINES AS TOPIC; HUMANS; INFLAMMATORY BOWEL DISEASES; ITALY; MALE; RISK ASSESSMENT; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84908258298     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.07.019     Document Type: Article

References (34)

1. Weise M., Bielsky M.C., De Smet K., et al. Biosimilars: what clinicians should know. Blood 2012, 120:5111-5117.
2. Schneider C.K., Vleminckx C., Gravanis I., et al. Setting the stage for biosimilar monoclonal antibodies. Nature Biotechnology 2012, 30:1179-1185.
3. D'Haens G.R., Panaccione R., Higgins P.D.R., et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis organization: when to start, when to stop, which drug to choose, and how to predict response?. American Journal of Gastroenterology 2011, 106:199-212.
4. Orlando A., Armuzzi A., Papi C., et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) clinical practice guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease 2011, 43:1-20.
5. Singh J.A., Wells G.A., Christensen R., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, CD008794.
6. Roblin X., Danese S., Peyrin-Biroulet L. Does anti-TNF therapy cost so many COINs?. Gastroenterology 2014, 146:309-311.
7. EMA guideline "Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues". EMEA/CHMP/BMWP/42832/2005.
8. EMA guideline "Similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues". EMEA/CHMP/BWP/49348/2005.
9. EMA guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. CHMP/BMWP/403543/2010.
10. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/news_and_events/news/2011/06/news_detail_001282.jsp%26murl=menus/news_and_events/news_and_events.jsp%26mid=wc0b01ac058004d5c1.
11. Press release: EMA recommends approval of first two monoclonal antibody biosimilars. EMA/390722/2013.
12. Biosimilar News. World's first biosimilar antibody is approved in Korea [14.11.12].
13. Gecse K.B., Khanna R., van den Brink G.R., et al. Biosimilars in IBD: hope or expectation?. Gut 2013, 62:803-807.
14. Danese S., Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). Journal of Crohn's and Colitis 2013, 7:586-589. the Governing Board and Operational Board of ECCO.
15. Argüelles-Arias F., Barreiro-de-Acosta M., Carballo F., et al. Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease. Revista Espanola de Enfermedades Digestivas 2013, 105:37-43.
16. Wojciechowski P.T., Myers M.M., Voronko P.J., et al. Making changes to a biopharmaceutical manufacturing process during development and commercial manufacturing. Process scale bioseparations for the biopharmaceutical industry 2006, 507-522. CRC Press, [chapter 18]. A.A. Shukla, M.R. Etzel, S. Gadam (Eds.).
17. Schumi J., Wittes J.T. Through the looking glass: understanding non-inferiority. Trials 2011, 12:106.
18. Sträter B. New pharmacovigilance rules in the EU and their impact on biosimilars and automatic substitution 2011, Scrip Regulatory Affairs.
19. AIFA. Position paper su farmaci biosimilari. [28.05.13]. http://www.agenziafarmaco.gov.it/it/content/position-paper-sui-farmaci-biosimilari-28052013.
20. Long G., Works J. Innovation in the biopharmaceutical pipeline: a multidimensional view 2013, http://www.innovation.org/documents/2013_innovation_in_the_biopharmaceutical_pipeline-analysis_group.pdf.
21. Ford A.C., Sandborn W.J., Khan K.J., et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. American Journal of Gastroenterology 2011, 106:644-659.
22. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. New England Journal of Medicine 1999, 340:1398-1405.
23. Fiocchi C. Closing fistulas in Crohn's disease-should the accent be on maintenance or safety?. New England Journal of Medicine 2004, 350:934-936.
24. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142:257-265.
25. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012, 61:918-932.
26. Seow C.H., Newman A., Irwin S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
27. VandeCasteele N., Ballet V., Van Assche G., et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 2012, 61:321.
28. Pariente B., Pineton de Chambrun G., et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2012, 18:1199-1206.
29. Nanda K.S., Cheifetz A.S., Moss A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. American Journal of Gastroenterology 2013, 108:40-47.
30. http://www.evaluategroup.com/Universal/View.aspx%3Ftype=Story%26id=320129.
31. Park W., Hrycaj P., Jeka S., et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Annals of the Rheumatic Diseases 2013, 72:1605-1612.
32. Yoo D.H., Hrycaj P., Miranda P., et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Annals of the Rheumatic Diseases 2013, 72:1613-1620.
33. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
34. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_inflectra_159493-eng.php.